GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Taiwan Bio Therapeutics 6892.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

25.75

+5.53%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Taiwan Bio Therapeutics

Its shares trade on Taipei Exchange under the ticker 6892.TWO. It has been listed since 13 May 2022. In the fiscal year to 31 December 2025, it reported revenue of TWD 50.4m and a net loss of TWD 381.6m. At that date it held total assets of TWD 1.35bn and shareholders' equity of TWD 729.6m.

Taiwan Bio Therapeutics Co., Ltd. engages in the research and development, manufacture, and sale of cell therapy. The company is headquartered in Zhubei, Hsinchu. The company went IPO on 2022-05-13. The main products include Chondrochymal for the treatment of degenerative arthritis of the knee, Biochymal for the treatment of difficult non-healing wounds caused by lower extremity ischemia, OmniMSC/TBPCB201 for the treatment of acute myocardial infarction, and MSC-VEGF for the treatment of lower extremity ischemia. The cell processing center (CPC) is engaged in the provision of a full set of CDMO services, process scale-up services, inspection and development services, and quality control commissioned inspection services. The firm mainly operates in Taiwan market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
13 May 2022

Leadership

Pay as last reported

  • Junyao YangChief Executive Officer, since 2024
  • Xiujuan ZhuangChief Financial Officer, Corporate Governance Officer, since 2024
  • Peishan CaiDirector
  • Mr. Chung-Liang LeeDirector
  • Ms. Yu-Ping YangDirector
  • Ms. Chunye ChenIndependent Director
  • Jinghong LiuIndependent Director
  • Liecheng WuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Chondrochymal treats degenerative arthritis of the knee in Taiwan market.
  • Biochymal addresses difficult non-healing wounds in lower extremity ischemia.
  • OmniMSC/TBPCB201 targets acute myocardial infarction treatment in Taiwan.

Weaknesses

  • Taiwan Bio Therapeutics operates solely in the Taiwan market.
  • The company's products are limited to specific medical conditions.
  • No international expansion mentioned in the business description.

Opportunities

  • OmniMSC/TBPCB201 could expand to treat acute myocardial infarction globally.
  • MSC-VEGF may address lower extremity ischemia in new markets.
  • CDMO services at CPC could attract global biotech clients.

Threats

  • Taiwan market dominance limits growth potential.
  • Competition in biotechnology sector is not specified.
  • No mention of regulatory challenges in the facts.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.